株式会社EXORPHIA
Tokyo, JP · 2 known investors
EXORPHIA develops extracellular vesicle (EV) technology for assisted reproductive medicine, focusing on cell-free IVF culture medium additives to improve embryo development and fertilization success rates. The company targets fertility clinics and academic institutions in reproductive medicine.
Also known as EXORPHIA · EXORPHIA Inc. · エクソーフィア
Founders & leadership
Investors · 2
Company profile
researched Aug 2026株式会社EXORPHIA (EXORPHIA, Inc.) is a Tokyo-based biotechnology company built around a platform for the manufacturing and engineering of extracellular vesicles (EVs), the nanoscale particles secreted by cells that are involved in intercellular communication. The company applies this platform to in vitro fertilization, conducting research and development aimed at improving embryo development and embryo-quality-related indicators.
EXORPHIA frames its positioning in assisted reproductive technology (ART) as a shift from embryo "selection" to embryo "improvement", with the stated goal of increasing the number of usable embryos and raising the cumulative live-birth rate per oocyte retrieval. Its disclosed development areas are next-generation IVF technology, drug-discovery applications, and research infrastructure.
Business model
The company commercializes the next-generation IVF technology derived from its EV platform itself, treating assisted reproductive medicine as its core business, while drug-discovery assets arising from the same platform are advanced toward practical use through joint development with and out-licensing to pharmaceutical companies.
Traction
Research output has been presented at Japanese reproductive medicine academic meetings, including two presentations at the 44th Annual Meeting of the Japan Society for Fertilization and Implantation and a presentation at the 67th Annual Meeting of the Japan Society for Ova Research, and joint research on non-invasive embryo assessment received the World Congress on In Vitro Fertilization Commemorative Prize in the basic science category.
Latest developments
In 2026 the company reported an award for joint research on non-invasive embryo evaluation, presentations at two Japanese reproductive medicine conferences, and updated recruitment postings as it hires for its EV technology programs.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions itself as a startup opening the future of assisted reproductive technology with EV technology, differentiating on embryo improvement rather than embryo selection.
Technology
An extracellular vesicle manufacturing and engineering platform. Research described includes umbilical cord mesenchymal stem cell (MSC)-derived EVs used to influence intra-embryonic dynamics, and non-invasive embryo evaluation based on quantifying differences in embryonic development characteristics through analysis of embryo motion.
Go-to-market
Assisted reproductive medicine (IVF) practice, plus pharmaceutical companies as partners for drug-discovery applications of the EV platform.
Geography
Headquartered in Tokyo, Japan, with activity centered on Japanese reproductive medicine academic societies.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsCollaborative research results on non-invasive embryo evaluation via intra-embryonic dynamics analysis, which quantifies differences in embryo development characteristics from motion, were awarded the World Congress on In Vitro Fertilization Commemorative Prize in the basic science category.
Presented research on control of intra-embryonic dynamics by umbilical cord MSC-derived extracellular vesicles and on non-invasive embryo evaluation.
Presented recent reproductive medicine research results at the society's academic meeting.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- 株式会社EXORPHIAexorphia.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 株式会社EXORPHIA do?
- Japanese biotechnology company applying extracellular vesicle technology to next-generation IVF and assisted reproductive medicine.
- Who founded 株式会社EXORPHIA?
- 株式会社EXORPHIA was founded by 口石 幸治 (Kohji Kuchiishi).
- Who are 株式会社EXORPHIA's investors?
- 株式会社EXORPHIA's investors include Coral Capital, Keio Innovation Initiative.
- Where is 株式会社EXORPHIA headquartered?
- 株式会社EXORPHIA is headquartered in Tokyo, JP.